| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Pershing Edward | 11% | $2,955,354 | 49,255,894 | Pershing Edward | 26 Nov 2025 | |||
| Rodrigues Dominic | 5.7% | $1,513,233 | 25,220,549 | Dominic Rodrigues | 02 Dec 2025 |
As of 30 Sep 2025, 6 institutional investors reported holding 229,411 shares of PROVECTUS BIOPHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (PVCT). This represents 0.05% of the company’s total 444,806,861 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 229,411 | $20,417 | +$53 | $0.09 | 6 |
| 2025 Q2 | 228,811 | $17,074 | $0.07 | 6 | |
| 2025 Q1 | 228,811 | $22,881 | $0.10 | 6 | |
| 2024 Q4 | 176,811 | $21,225 | -$5,000 | $0.12 | 5 |
| 2024 Q3 | 226,811 | $22,320 | -$196 | $0.10 | 6 |
| 2024 Q2 | 228,811 | $28,570 | $0.13 | 6 | |
| 2024 Q1 | 178,811 | $32,710 | $0.18 | 5 | |
| 2023 Q4 | 228,811 | $21,859 | $0.10 | 6 | |
| 2023 Q3 | 218,620 | $18,155 | -$865 | $0.08 | 5 |
| 2023 Q2 | 226,270 | $25,970 | $0.11 | 6 | |
| 2023 Q1 | 226,270 | $36,784 | $0.16 | 6 | |
| 2022 Q4 | 218,620 | $23,232 | -$2,000 | $0.11 | 5 |
| 2022 Q3 | 256,650 | $12,000 | -$2,000 | $0.05 | 6 |
| 2022 Q2 | 292,309 | $17,000 | -$158,062 | $0.06 | 6 |
| 2022 Q1 | 2,616,923 | $176,000 | -$1,099 | $0.06 | 6 |
| 2021 Q4 | 2,639,300 | $146,000 | +$130,000 | $0.06 | 6 |
| 2021 Q3 | 236,520 | $15,000 | +$8 | $0.06 | 6 |
| 2021 Q2 | 236,857 | $16,000 | $0.07 | 6 | |
| 2021 Q1 | 236,857 | $16,000 | +$1,252 | $0.07 | 6 |
| 2020 Q4 | 218,457 | $13,000 | +$1,000 | $0.06 | 5 |
| 2020 Q3 | 196,000 | $16,000 | $0 | $0.08 | 4 |
| 2020 Q2 | 197,657 | $8,000 | +$3,000 | $0.04 | 4 |
| 2020 Q1 | 120,000 | $6,000 | $0.05 | 2 | |
| 2019 Q4 | 120,000 | $7,000 | -$1,000 | $0.06 | 2 |
| 2019 Q3 | 130,600 | $9,000 | $0.07 | 3 | |
| 2019 Q2 | 130,600 | $8,000 | -$1,000 | $0.06 | 3 |
| 2019 Q1 | 152,600 | $9,000 | -$1,000 | $0.06 | 4 |
| 2018 Q4 | 170,600 | $9,000 | -$2,000 | $0.05 | 4 |
| 2018 Q3 | 199,100 | $14,000 | +$3,000 | $0.07 | 5 |
| 2018 Q2 | 150,600 | $11,000 | -$1,000 | $0.08 | 3 |
| 2018 Q1 | 169,250 | $10,000 | $0.06 | 4 | |
| 2017 Q4 | 169,250 | $13,000 | +$5,000 | $0.08 | 4 |
| 2017 Q3 | 100,000 | $3,000 | $0.03 | 1 | |
| 2017 Q2 | 100,000 | $3,000 | -$1,000 | $0.03 | 1 |
| 2017 Q1 | 112,205 | $5,000 | -$1,000 | $0.06 | 2 |
| 2016 Q4 | 179,500 | $4,000 | -$1,032,000 | $0.02 | 2 |
| 2016 Q3 | 10,567,842 | $1,045,000 | +$142,088 | $0.10 | 29 |
| 2016 Q2 | 8,466,294 | $3,131,000 | -$217,289 | $0.37 | 36 |
| 2016 Q1 | 8,998,709 | $3,409,000 | -$309,049 | $0.38 | 35 |
| 2015 Q4 | 9,807,578 | $3,825,000 | -$399,293 | $0.39 | 34 |
| 2015 Q3 | 10,662,835 | $6,127,000 | -$1,079,739 | $0.57 | 35 |
| 2015 Q2 | 12,127,015 | $6,548,771 | +$4,252,641 | $0.54 | 30 |
| 2015 Q1 | 4,226,892 | $3,443,272 | -$543,897 | $0.81 | 31 |
| 2014 Q4 | 4,896,691 | $3,914,905 | +$570,722 | $0.80 | 34 |
| 2014 Q3 | 4,110,787 | $4,188,897 | +$2,916,157 | $1.02 | 27 |
| 2014 Q2 | 1,274,256 | $1,096,621 | +$1,015,621 | $0.86 | 26 |
| 2014 Q1 | 75,000 | $185,000 | +$89,000 | $2.46 | 4 |